TELA Bio Q2 revenue $10.4M (+38% YoY); FY2022 guidance $42-45M

TELA Bio, Inc.

2022-Q2 EPS reported -$1.62 revenue$18,637,000

Q2 revenue of $10.4M, up 38% YoY; OviTex revenue +22%, OviTex PRS +87%.
Net loss widened to $12.7M from $8.3M; operating loss $10.2M vs $7.3M.
FY2022 revenue guidance $42-45M (43-53% growth); COVID could impact.
Cash $27.7M at June 30; secured up to $50M debt facility from MidCap Financial.
Entered GPO contract with Premier Inc. covering ~4,400 hospitals, effective October 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.